Skip to main content

Table 1 The relationship between the level of LP-PLA2 and degree of coronary artery stenosis

From: The relationship of lipoprotein-associated phospholipase A2 activity with the seriousness of coronary artery disease

Group

Control

Single

Multiple

P

N

294

366

396

 

Age (years)

60.63 ± 11.96

63.16 ± 12.88

65.23 ± 10.93*

0.113

Male(%)

204 (69.4)

306 (83.6)

282 (71.2)

0.237

Smoking(%)

84 (28.6)

150 (41.0)

162 (40.9)

0.315

Hypertension(%)

168 (57.1)

216 (59.0)

276 (69.7)

0.305

Diabetes (%)

54 (18.4)

96 (26.2)

120 (30.3)

0.345

FBG (mmol/L) a

5.35 (4.39–8.56)

6.04 (5.32–10.25)

6.27 (4.28–10.45)*

0.204

Lp(a)(mmol/L) a

230.39 (112.06–428.32)

262.12 (121.46–675.28)

346.55 (176.55–728.36)*

0.059

TC (mmol/L)

4.40 ± 1.13

4.20 ± 0.20

4.52 ± 1.28

0.291

TG (mmol/L)

1.52 ± 0.97

1.51 ± 0.87

1.78 ± 0.87

0.213

LDL-C (mmol/L)

2.82 ± 0.93

2.59 ± 0.84

2.88 ± 1.02

0.192

HDL-C (mmol/L)

1.17 ± 0.28

1.09 ± 0.23

1.04 ± 0.26 *

0.027

Lp-PLA2(ng/ml) a

172.83 (92.35–296.42)

230.95 (115.69–406.35)*

289.24 (132.11–430.21)*#

< 0.001

  1. aindicated median and inter-quartile range, FBG Fasting blood glucose, Lp(a) Lipoprotein(a), TC Total cholesterol, TG Triglyceride, LDL-C Low density lipoprotein-cholesterol, HDL-C High density lipoprotein-cholesterol, Lp-PLA2 Lipoprotein associated-phospholipase A2. *P < 0.05 versus control group, #P < 0.05 versus single group